Navigation Links
OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy

HOUSTON, Nov. 21, 2011 /PRNewswire/ -- OrthoAccel® Technologies, Inc. announced this week that it has finalized a distribution agreement with Micerium S.p.A. based in Avegno for exclusive distribution rights of the AcceleDent™ System in Italy.

The AcceleDent™ System is currently being sold outside the USA and was first introduced in the United Kingdom in October 2009.  The lightweight appliance, used to speed up the rate of orthodontic treatment, is intended for 20 minutes of daily use.  Patients simply bite down on the Mouthpiece to hold it in place, which allows freedom of the hands to engage in other routine, daily activities during the treatment session.  Patients have reported using the appliance while engaged in a variety of activities, including homework, watching television, reading and listening to music.

Mike Kaufman, Vice President of Marketing and Business Development for OrthoAccel® commented, "Micerium is the most recent addition to our growing network of European distributors.  Italy is a key international market for us and it bodes well that this market leader shares our philosophy and excitement for how AcceleDent™ can change orthodontic treatment."  AcceleDent™ was introduced to the Italian orthodontic community during the SIDO meeting in Rome November 11-13.  Dr. Ravindra Nanda reported on the recent results from a randomized, controlled clinical trial conducted at the University of Texas Health Science Center at San Antonio under the guidance of Dr. Dubravko Pavlin where AcceleDent™ demonstrated, with statistical significance, that tooth movement could be safely accelerated by 38% to 50% during space closure and even more so during the alignment phase.

This definitive distribution agreement between OrthoAccel® and Micerium formalizes the intent to partner together that was initiated under a Terms of Agreement in June of this year.  Ottaviano Miceli, CEO of Micerium, expressed his enthusiasm, "I am excited about this new project. Our company has always paid attention to market innovations and we believe that AcceleDent is great news - a simple product that will bring many benefits to the orthodontic treatment in terms of time savings and results. In a short time we have already seen a great interest and desire to discover and try AcceleDent by the Italian orthodontists who want to offer the best treatment to their patients. " 

OrthoAccel® has been selling the AcceleDent™ System outside the USA since October 2009.  FDA clearance is pending based on an application submitted earlier this year.

About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

About the
AcceleDent™ System
represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating bone biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works complementary with all existing orthodontic technologies. AcceleDent™ is neither FDA cleared nor FDA approved; it is currently investigational only in the United States. More information can be found at and or requested via

SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
6. Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
7. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space
8. AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing
9. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
10. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
11. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... November 24, 2015 SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):